Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
Affected Genes

Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
description Ratio Regulation Gene Gene Ontology Class Accession Minimum Ratio Maximum Ratio
Results: HTML CSV LaTeX
Showing element 1 to 50 of 103 in total
Gene Ontology: protein binding
Class: molecular function

\def\wcA{0.25\textwidth}
\def\wcB{0.25\textwidth}
\def\wcC{0.25\textwidth}
\begin{longtable}{|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Ratio\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Regulation\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ADAM 12 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain 12) (Meltrin alpha). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.76994\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ADAM 22 precursor (A disintegrin and metalloproteinase domain 22) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 2) (Metalloproteinase-disintegrin ADAM22-3). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.16499\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Amyloid beta A4 precursor protein-binding family A member 2 (Neuron- specific X11L protein) (Neuronal Munc18-1-interacting protein 2) (Mint-2) (Adapter protein X11beta). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.49031\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Antigen KI-67. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.73211\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
AP-3 complex subunit sigma-1 (Adapter-related protein complex 3 sigma- 1 subunit) (Sigma-adaptin 3a) (AP-3 complex sigma-3A subunit) (Sigma- 3A-adaptin) (Clathrin-associated/assembly/adapter protein, small 3). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
4.07995\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
AP-3 complex subunit sigma-2 (Adapter-related protein complex 3 sigma- 2 subunit) (Sigma-adaptin 3b) (AP-3 complex sigma-3B subunit) (Sigma- 3B-adaptin). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.50284\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Ataxin-7 (Spinocerebellar ataxia type 7 protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.29381\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Atlastin-2 (ADP-ribosylation factor-like protein 6-interacting protein 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.24964\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Autophagy-related protein 10 (APG10-like). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.28319\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Bcl-2-interacting killer (Apoptosis inducer NBK) (BP4) (BIP1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.21871\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
BET1 homolog (Golgi vesicular membrane-trafficking protein p18) (hBET1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.48474\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Bone morphogenetic protein 2 precursor (BMP-2) (BMP-2A). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.49558\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
BTB/POZ domain-containing protein KCTD8. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.73291\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Calmodulin-like protein 5 (Calmodulin-like skin protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.61347\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Calpain-3 (EC 3.4.22.54) (Calpain L3) (Calpain p94) (Calcium-activated neutral proteinase 3) (CANP 3) (Muscle-specific calcium-activated neutral protease 3) (nCL-1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.87038\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Chromodomain helicase-DNA-binding protein 4 (EC 3.6.1.-) (ATP- dependent helicase CHD4) (CHD-4) (Mi-2 autoantigen 218 kDa protein) (Mi2-beta). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.78439\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Cisplatin resistance-associated overexpressed protein (cAMP regulatory element-associated protein 1) (CRE-associated protein 1) (CREAP-1) (Luc7A) (Okadaic acid-inducible phosphoprotein OA48-18). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.91954\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
CLIP-associating protein 2 (Cytoplasmic linker-associated protein 2) (hOrbit2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.29151\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Contactin-3 precursor (Brain-derived immunoglobulin superfamily protein 1) (BIG-1) (Plasmacytoma-associated neuronal glycoprotein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.99682\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Cullin-4B (CUL-4B). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.49271\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Cyclin-A2 (Cyclin-A). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.45635\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
DAZ-associated protein 2 (Deleted in azoospermia-associated protein 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
4.90535\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Deoxyribonuclease-2-alpha precursor (EC 3.1.22.1) (Deoxyribonuclease II alpha) (DNase II alpha) (Acid DNase) (Lysosomal DNase II) (R31240\_2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.19545\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
DNA-directed RNA polymerase III subunit RPC8 (RNA polymerase III subunit C8) (DNA-directed RNA polymerase III subunit H) (DNA-directed RNA polymerase III subunit 22.9 kDa polypeptide). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
6.56408\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
E3 ubiquitin-protein ligase CHFR (EC 6.3.2.-) (Checkpoint with forkhead and RING finger domains protein) (RING finger protein 196). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.30869\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.21473\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
F-box only protein 15. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.33107\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
F-box/WD repeat protein 5 (F-box and WD-40 domain protein 5). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.50715\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABA(A) receptor-associated protein-like 1) (Glandular epithelial cell protein 1) (GEC-1) (Early estrogen-regulated protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.33817\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Geminin. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.35125\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Golgin subfamily B member 1 (Giantin) (Macrogolgin) (372 kDa Golgi complex-associated protein) (GCP372). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.45148\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
GTP-binding protein Rhes precursor (Ras homolog enriched in striatum) (Tumor endothelial marker 2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.64872\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 2 (Transducin beta chain 2) (G protein beta 2 subunit). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.54799\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Insulin-induced gene 1 protein (INSIG-1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.23845\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Kelch-like protein 34. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.21698\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
leucine-rich repeat neuronal 6A \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2.79087\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Low density lipoprotein receptor adapter protein 1 (Autosomal recessive hypercholesterolemia protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.30207\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
LRRC44 protein. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.41794\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
MAP/microtubule affinity-regulating kinase 3 (EC 2.7.11.1) (Cdc25C- associated protein kinase 1) (cTAK1) (C-TAK1) (Serine/threonine protein kinase p78) (Ser/Thr protein kinase PAR-1) (Protein kinase STK10). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.34969\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Melanoma-associated antigen B2 (MAGE-B2 antigen) (DSS-AHC critical interval MAGE superfamily 6) (DAM6) (MAGE XP-2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.27802\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Methyl-CpG-binding domain protein 1 (Methyl-CpG-binding protein MBD1) (Protein containing methyl-CpG-binding domain 1). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.22576\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
N-glycosylase/DNA lyase [Includes: 8-oxoguanine DNA glycosylase (EC 3.2.2.-); DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP lyase)]. \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.35022\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
NEDD4-binding protein 2 (EC 3.-.-.-) (N4BP2) (BCL-3-binding protein). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3.21581\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Neurexin-2-alpha precursor (Neurexin II-alpha). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.2734\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear factor of activated T-cells, cytoplasmic 3 (NF-ATc3) (NFATc3) (T cell transcription factor NFAT4) (NF-AT4) (NFATx). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
5.32612\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
down\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear pore complex protein Nup153 (Nucleoporin Nup153) (153 kDa nucleoporin). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.48389\vspace{3pt}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear receptor ROR-alpha (Retinoid-related orphan receptor-alpha) (Nuclear receptor RZR-alpha). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.98137\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Nuclear RNA export factor 2 (TAP-like protein 2) (TAPL-2). \vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.19207\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
up\vspace{3pt}}}\\\cline{1-2}
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
NULL\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
1.18711\vspace{3pt}}&\\\cline{2-2}
&\parbox{\wcB}{\vspace{3pt}\noindent
1.40093\vspace{3pt}}&\\\hline
nd{longtable}

Legend:
- The Ratio specifies how much this gene is up/down regulated. When up- or down-regulated must this value respectively be multiplied/divided to obtain the MK5 on concentration based on the MK5 off concentration.

 - The Regulation specifies how this gene is affected when going from the MK5 off cells to the MK5 on cells. 

 - The Class refers to the ontology category, which can be molecular_function, biological_process or cellular_component. 

 - The Gene Ontology terms as linked to the specific gene.

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Accession is the GO accession key. 

 - Minimum Ratio is the lowest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

 - Maximum Ratio is the highest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.
- http://analysis.yellowcouch.org/